Consensus Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 24/06/2025 BST			5-day change	1st Jan Change
325.00 ^USD	+3.79%		+5.28%	+38.12%

06-18	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM

Evolution of the Average Target: Alnylam Pharmaceuticals, Inc.

Evolution of the Target Price: Alnylam Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Alnylam Pharmaceuticals, Inc.

909986fd91e0ac56d314c3.dRzUXwQbOf2YQyIwO3h-iJcNQNJCFyD88tv-evo5q14.OU2CK2ZhdcmsJxVcYyEP-tZXcJ96LlmooZS0AJZe2AtHb78OSHRyxckREg~67b43a104e236690a56ae781191a12e3

Analysts' recommendations: Alnylam Pharmaceuticals, Inc.

UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	05-02	MT
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	04-17	MT
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280	03-24	MT
Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH…	03-24
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating	03-21	MT
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating	03-21	MT
Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...	02-25
Analyst recommendations: Unilever, Glencore, Tesla, XPO, Celanese Corp…	02-24
Analyst recommendations: Nike, Roku, Tesla, XPO, Celanese Corp...	02-24
Analyst recommendations: Alphabet, Lear Corp, Molson Coors, Hasbro, Visa...	02-21
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating	02-14	MT
Mirae Asset Downgrades Alnylam Pharmaceuticals to Hold, Price Target is $236	12-02	MT
Analyst recommendations: Constellation Energy, Dell, HP, Target, J Sainsbury...	11-28
Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205	11-12	MT
Analyst recommendations: Airbnb, Estee Lauder, Fortinet, Robinhood, GSK...	11-12
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals...	11-01
Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target	16/10/24	MT
China Merchants Initiates Alnylam Pharmaceuticals at Buy With $360 Price Target	20/09/24	MT
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained	19/08/24	MT
Analyst recommendations: Biogen, Cloudflare, Doordash, Moderna, Diageo...	12/08/24
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,089,960, According to a Recent SEC Filing	05/08/24	MT
Chardan Adjusts Alnylam Pharmaceuticals' PT to $300 From $265, Keeps Buy Rating	02/08/24	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $300 From $265, Keeps Outperform Rating	02/08/24	MT
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	23/07/24
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing	15/07/24	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Ecart obj. / dr
ALNYLAM PHARMACEUTICALS, INC.		+2.98%
ELI LILLY AND COMPANY		+23.53%
JOHNSON & JOHNSON		+11.8%
ABBVIE INC.		+13.66%
NOVO NORDISK A/S		+46.94%
ROCHE HOLDING AG		+16.17%
NOVARTIS AG	-	+1.47%
ASTRAZENECA PLC		+27.32%
MERCK & CO., INC.		+26.98%
AMGEN INC.		+15.51%
Average		+18.64%
Weighted average by Cap.		+20.76%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

325.00USD

Average target price

322.46USD

Spread / Average Target

-0.78%

High Price Target

500.00USD

Spread / Highest target

+53.85%

Low Price Target

212.00USD

Spread / Lowest Target

-34.77%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
BofA Securities
JPMorgan Chase
RBC Capital Markets
Mirae Asset Group
Wolfe Research
Scotiabank
China Merchants
HC Wainwright
Chardan Research
Goldman Sachs
Morgan Stanley
Wells Fargo Securities
Oppenheimer
Bernstein
Evercore ISI
TD Cowen
BMO Capital
Citigroup
Needham & Co.
Raymond James
Canaccord Genuity
EF Hutton
SVB Securities LLC
Piper Sandler
Berenberg Bank
Jefferies & Co.
Cantor Fitzgerald
Guggenheim
William Blair & Co.
SVB Leerink
Stifel Nicolaus
Chardan
Barclays
Cowen